
3 Billion Pairs
AI-powered genetic testing and drug discovery for rare diseases.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Seed | ||
Total Funding | 000k |
Related Content
3billion is a South Korean company specializing in artificial intelligence-based genetic diagnostics for rare diseases. Founded in October 2016 by CEO Changwon Keum, the company originated as a spinoff from Macrogen, a genomic services provider, initially to offer direct-to-consumer genomic screening for rare diseases. The company's name is a reference to the approximately 3 billion base pairs that make up the human genome.
The firm's business model centers on providing cost-effective and precise genetic testing services to hospitals, clinics, and pharmaceutical companies globally. Their core products include whole-exome and whole-genome sequencing services, named 3B-EXOME and 3B-GENOME respectively. A key differentiator is their commitment to reanalyzing undiagnosed cases as new scientific discoveries about diseases are made. This approach is powered by an AI system that significantly reduces the time and cost of interpreting genetic variations, cutting down a process that traditionally takes 20-40 hours to just five minutes.
In addition to diagnostics, 3billion has expanded into drug discovery. The company leverages its accumulated genomic and clinical data from over 80,000 patients to power an AI platform that identifies new drug targets and predicts candidate molecules. This platform is designed to accelerate the development of treatments for rare diseases. The company collaborates with pharmaceutical partners to advance these efforts, aiming to create a seamless journey from diagnosis to treatment. Having listed on the KOSDAQ in November 2024, 3billion serves over 700 institutions in more than 70 countries.
Keywords: rare disease diagnostics, genetic testing, AI drug discovery, whole genome sequencing, whole exome sequencing, precision medicine, genomic data analysis, South Korean biotech, Macrogen spinoff, Changwon Keum, genetic variant interpretation, drug candidate discovery, orphan diseases, clinical genomics, bioinformatics, DNA sequencing, KOSDAQ, healthcare technology, molecular diagnostics, pharmacogenomics